MedTrace Logo

Amlodipine And Olmesartan Medoxomil In Hypertensive Filipino Patients

NCT01200407 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 615

Last updated 2021-08-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine the safety, tolerability and efficacy of Amlodipine and Olmesartan medoxomil among Hypertensive Filipino patients.

Conditions

Interventions

DRUG

Amlodipine + Olmesartan medoxomil

start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-09
Primary Completion
2014-01-04
Completion
2014-01-04

Countries

  • Philippines

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01200407 on ClinicalTrials.gov